PI3K, AKT, and dual PI3K/mTOR inhibitors enhance FOXO3 nuclear localisation in breast cancer cells which is implicated in both sensitivity and feedback mediated resistance to pathway inhibition14,15. The gene discussed is AKT1; the disease is breast carcinoma.